Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probiotic yeast typically refers to Saccharomyces cerevisiae var. boulardii, a live, non-pathogenic yeast strain well-studied for its ability to protect and restore gut microbiota, inhibit harmful pathogens, regulate immune responses, and promote intestinal health. It is classified taxonomically as a member of the yeast kingdom, specifically the genus Saccharomyces and the species S. cerevisiae (with boulardii as a variant/strain). Its use as a probiotic is mainly in gastrointestinal disorders; it is not a molecular target but functions as a living therapeutic microorganism. While clinical studies support its safety and efficacy for most populations, caution is advised in immunocompromised individuals due to risk of systemic infection.
Competitive exclusion of pathogenic microbes; Neutralization of bacterial toxins; Production of bioactive metabolites with antimicrobial properties; Enhancement of mucin and barrier protective mechanisms; Immunomodulation by stimulating cytokine and immunoglobulin production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Saccharomyces cerevisiae var. boulardii (S. boulardii).